Dabigatran for Mitral Stenosis Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 370 participants.

Also called NCT04045093

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 370 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04045093
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Hong Kong SAR China (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04045093. Randomized; no masking; primary purpose prevention. Start 2020-10-22 (actual); primary completion 2026-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dabigatran for Mitral Stenosis Atrial Fibrillation
Acronym
David-MS
Condition
Mitral Stenosis
Intervention (Drug)
Dabigatran etexilate
Intervention (Drug)
Warfarin
Lead sponsor
The University of Hong Kong (class: other)

Record details

Record id
cardio:ct-nct04045093
Content hash
abf80748986e6a829f3d532e370a51f2a481b814b34fc7633658d8542d02f97a